Pulmonary Arterial Hypertension Clinical Trials in Omaha, Nebraska

4 studies are recruiting for pulmonary arterial hypertension in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

   The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   USA028, Omaha, Nebraska

   Locations

   26 in total

   Run by

   Insmed Incorporated

   See if you can join NCT07481981 on ClinicalTrials.gov

2. A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

   Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) tre…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University Of Nebraska Medical Center ( Site 1053), Omaha, Nebraska

   Locations

   136 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07218029 on ClinicalTrials.gov

3. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

   The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

   Stage

   Not phased

   Ages

   0 to 20

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Locations

   52 in total

   Run by

   Duke University

   See if you can join NCT04278404 on ClinicalTrials.gov

4. Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

   This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Locations

   120 in total

   Run by

   Gossamer Bio USA, Inc.

   See if you can join NCT06274801 on ClinicalTrials.gov